

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1648rxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 23:09:28 ON 14 OCT 2008

FILE 'MEDLINE' ENTERED AT 23:09:53 ON 14 OCT 2008

FILE 'BIOSIS' ENTERED AT 23:09:53 ON 14 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 23:09:53 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> relaxin-3
L1 199 RELAXIN-3

=> 11 and feed?
L2 19 L1 AND FEED?

=> 11 and weight
L3 8 L1 AND WEIGHT

=> 12 or 13
L4 22 L2 OR L3

```
=> dup rem 14
PROCESSING COMPLETED FOR L4
L5          12 DUP REM L4 (10 DUPLICATES REMOVED)
```

=> 15 and 1970-2005/py
L6 4 L5 AND 1970-2005/PY

=> d_ibib 16 1-4

L6 ANSWER 1 OF 4 MEDLINE on STN
ACCESSION NUMBER: 2005355604 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15845619
TITLE: Central relaxin-3 administration causes hyperphagia in male Wistar rats.

AUTHOR: McGowan B M C; Stanley S A; Smith K L; White N E; Connolly M M; Thompson E L; Gardiner J V; Murphy K G; Ghatei M A; Bloom S R
 CORPORATE SOURCE: Endocrine Unit, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, United Kingdom.
 SOURCE: Endocrinology, (2005 Aug) Vol. 146, No. 8, pp. 3295-300. Electronic Publication: 2005-04-21. Journal code: 0375040. ISSN: 0013-7227.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 (RESEARCH SUPPORT, NON-U.S. GOV'T)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 200509
 ENTRY DATE: Entered STN: 13 Jul 2005
 Last Updated on STN: 27 Sep 2005
 Entered Medline: 26 Sep 2005

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1289617 CAPLUS
 DOCUMENT NUMBER: 144:32547
 TITLE: Methods and compositions for control of fetal growth via modulation of relaxin
 INVENTOR(S): Unemori, Elaine
 PATENT ASSIGNEE(S): Bas Medical, Inc., USA
 SOURCE: PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115435	A2	20051208	WO 2005-US15248	20050502 <--
WO 2005115435	A3	20070125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247332	A2	20051208	AU 2005-247332	20050502 <--
AU 2005247332	A1	20051208		
CA 2563433	A1	20051208	CA 2005-2563433	20050502 <--
US 20060247163	A1	20061102	US 2005-120582	20050502
EP 1753449	A2	20070221	EP 2005-780049	20050502
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
JP 2007535574	T	20071206	JP 2007-511088	20050502
US 20060247172	A1	20061102	US 2006-478267	20060628
US 20080108572	A1	20080508	US 2007-981338	20071031
PRIORITY APPLN. INFO.:			US 2004-567353P	P 20040430
			US 2005-120582	A3 20050502
			WO 2005-US15248	W 20050502

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1016407 CAPLUS
 DOCUMENT NUMBER: 144:101114
 TITLE: The relaxin gene-knockout mouse: a model of progressive fibrosis
 AUTHOR(S): Samuel, Chrishan S.; Zhao, Chongxin; Bathgate, Ross A. D.; Du, Xiao-Jun; Summers, Roger J.; Amento, Edward P.; Walker, Lesley L.; McBurnie, Mary; Zhao, Ling; Tregear, Geoffrey W.
 CORPORATE SOURCE: Howard Florey Institute of Experimental Physiology & Medicine, University of Melbourne, Parkville, Victoria, 3010, Australia
 SOURCE: Annals of the New York Academy of Sciences (2005), 1041(Relaxin and Related Peptides), 173-181
 CODEN: ANYAA9; ISSN: 0077-8923
 PUBLISHER: New York Academy of Sciences
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:823818 CAPLUS
 DOCUMENT NUMBER: 143:223700
 TITLE: Binding of relaxin-3 to G-protein-coupled receptor 135 (GPCR135) and a role in promoting food intake and body weight gain and obesity: use for antiobesity drug screening
 INVENTOR(S): Hida, Takayuki; Hirohashi, Tomoko; Sawai, Toru; Seiki, Takashi; Takahashi, Eiki; Kosasa, Michiko; Harada, Kokichi; Arai, Toru
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075641	A1	20050818	WO 2005-JP1887	20050209 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210369	A1	20050818	AU 2005-210369	20050209 <--
CA 2555469	A1	20050818	CA 2005-2555469	20050209 <--
EP 1721971	A1	20061115	EP 2005-709939	20050209
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

CN 1918290 A 20070221 CN 2005-80004472 20050209
US 20070054850 A1 20070308 US 2006-588542 20060807
KR 2007004699 A 20070109 KR 2006-718442 20060908
PRIORITY APPLN. INFO.: JP 2004-31591 A 20040209
JP 2004-368509 A 20041220
WO 2005-JP1887 W 20050209
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> takayuki?/au and hida?/au
L7 0 TAKAYUKI?/AU AND HIDA?/AU

=> tomoko?/au and sekiya?/au
L8 0 TOMOKO?/AU AND SEKIYA?/AU

L9 0 TORU?/AU AND SAWAI?/AI

=> toru?/au and sawai?/au
L10 0 TORU?/AU AND SAWAI?/AU

L11 0 TAKASHI?/AU AND SEIKI?/AI

=> takashi?/au and seiki?/au
L12 9 TAKASHI?/AU AND SEIKI?/AU

=> eiki?/au and takahashi?/au
L13 2 EIKI?/AU AND TAKAHASHI?/AU

=> michiko?/au and kosasa?/au
L14 0 MICHIKO?/AU AND KOSASA?/AU

=> kokichi?/au and harada?/au
L15 0 KOKICHI?/AU AND HARADA?/AU

=> tohru?/au and arai?/au
L16 0 TOHRU?/AU AND ARAI?/AU

=> l12 and l13
L17 0 L12 AND L13

=> l12 or l13
L18 11 L12 OR L13

=> l6 and l18
L19 0 L6 AND L18

=> d abs l6 1-4

L6 ANSWER 1 OF 4 MEDLINE on STN
AB Relaxin-3 (INSL-7) is a recently discovered member of
the insulin superfamily. Relaxin-3 mRNA is expressed
in the nucleus incertus of the brainstem, which has projections to the
hypothalamus. Relaxin-3 binds with high affinity to
the LGR7 receptor and to the previously orphan G protein-coupled receptor
GPCR135. GPCR135 mRNA is expressed predominantly in the central nervous
system, particularly in the paraventricular nucleus (PVN). The presence
of relaxin-3 and these receptors in the PVN led us to
investigate the effect of central administration of relaxin-
3 on food intake in male Wistar rats. The receptor involved in
mediating these effects was also investigated. Intracerebroventricular
injections of human relaxin-3 (H3) to satiated rats

significantly increased food intake 1 h post administration in the early light phase [0.96 +/- 0.16 g (vehicle) vs. 1.81 +/- 0.21 g (180 pmol H3), P < 0.05] and the early dark phase [2.95 +/- 0.45 g (vehicle) vs. 4.39 +/- 0.39 g (180 pmol H3), P < 0.05]. Intra-PVN H3 administration significantly increased 1-h food intake in sated rats in the early light phase [0.34 +/- 0.16 g (vehicle) vs. 1.23 +/- 0.30 g (18 pmol H3), P < 0.05] and the early dark phase [4.43 +/- 0.32 g (vehicle) vs. 6.57 +/- 0.42 g (18 pmol H3), P < 0.05]. Feeding behavior increased after intra-PVN H3. Equimolar doses of human relaxin-2, which binds the LGR7 receptor but not GPCR135, did not increase feeding. Hypothalamic neuropeptide Y, proopiomelanocortin, or agouti-related peptide mRNA expression did not change after acute intracerebroventricular H3. These results suggest a novel role for relaxin-3 in appetite regulation.

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compds. that modulate relaxin and/or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB A review. Relaxin is well known for its actions on collagen remodeling. To improve our understanding of the physiol. role(s) of relaxin, the relaxin gene-knockout (RLX-KO) mouse was established by our group and subsequently phenotyped. Pregnant RLX-KO mice underwent inadequate development of the pubic symphysis as well as the mammary glands and nipples compared to wild-type mice, thus preventing lactation. Later studies showed that these deficiencies were associated with increased collagen, primarily in the nipple and vagina. Anal. of male RLX-KO mice also demonstrated inadequate reproductive tract development. The testis, epididymis, and prostate of RLX-KO mice showed delayed tissue maturation and growth associated with increased collagen deposition. In nonreproductive tissues, an age-related increase in interstitial collagen (fibrosis) was also detected in the lung, heart, and kidneys of RLX-KO mice and was associated with organ dysfunction. From 6-9 mo of age and onwards, all organs of RLX-KO mice, particularly male mice, underwent progressive increases in tissue weight and collagen content (all P < .05) compared with wild-type animals. The increased fibrosis contributed to bronchiolar epithelium thickening and alveolar congestion (lung), atrial hypertrophy and increased ventricular chamber stiffness (heart) in addition to glomerulosclerosis (kidney). Treatment of RLX-KO mice with recombinant human relaxin in early and developed stages of fibrosis caused the reversal of collagen deposition in the lung, heart, and kidneys. Together, these findings suggest that relaxin is a naturally occurring inhibitor of collagen deposition during normal development, aging, and pregnancy and can be used to prevent the progression of fibrosis.

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AB The present invention provides a polypeptide having useful effects of promoting food intake and body weight gain and causing obesity; drugs for diseases containing this polypeptide; a method of screening substances activating or inhibiting a receptor for the polypeptide; and food intake regulating agents, drugs for obesity, diabetes and so on containing a substance inhibiting the expression of the polypeptide, etc. By intracerebroventricularly administering relaxin-3 to

rats and observing feed intake, body weight, fat amount, etc. after the administration, it was found that relaxin-3 has effects of promoting food intake and body weight gain and cause obesity.

=> d his

(FILE 'HOME' ENTERED AT 23:09:28 ON 14 OCT 2008)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 23:09:53 ON 14 OCT 2008

L1 199 RELAXIN-3
L2 19 L1 AND FEED?
L3 8 L1 AND WEIGHT
L4 22 L2 OR L3
L5 12 DUP REM L4 (10 DUPLICATES REMOVED)
L6 4 L5 AND 1970-2005/PY
L7 0 TAKAYUKI?/AU AND HIDA?/AU
L8 0 TOMOKO?/AU AND SEKIYA?/AU
L9 0 TORU?/AU AND SAWAI?/AI
L10 0 TORU?/AU AND SAWAI?/AU
L11 0 TAKASHI?/AU AND SEIKI?/AI
L12 9 TAKASHI?/AU AND SEIKI?/AU
L13 2 EIKI?/AU AND TAKAHASHI?/AU
L14 0 MICHIKO?/AU AND KOSASA?/AU
L15 0 KOKICHI?/AU AND HARADA?/AU
L16 0 TOHRU?/AU AND ARAI?/AU
L17 0 L12 AND L13
L18 11 L12 OR L13
L19 0 L6 AND L18

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	68.72	68.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

STN INTERNATIONAL LOGOFF AT 23:20:56 ON 14 OCT 2008